Vedolizumab (anti-α4β7-integrin), CAS 943609-66-3

Product Description: Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75./[2]Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9.

CAS Number: 943609-66-3

Molecular Weight: N/A

Compound Purity: 99.90

Research Area: Inflammation/Immunology

Solubility: 10 mM in H2O

Target: Integrin

• Artikelnummer: MEXHY-P9911A-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9911A-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK